/
ADC Therapeutics is a commercial-stage global pioneer in the field of antibody drug conjugates ( ADCs ), transforming treatment for patients through our focused portfolio with ZYNLONTA (loncastuximab tesirine-lpyl), a CD19-directed ADC. Food and Drug Administration ( FDA ) and conditional approval from the European Commission, China National Medical Products Administration ( NMPA ) and…
The business is unprofitable at the operating level (-149.34% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Revenue up 14.9% YoY with margins expanding 35.1pp.
Negative free cash flow of -$141M. The business is consuming cash, not generating it.
Profitability & Returns
Revenue (TTM)
$79M
▲ +14.9% YoY
Net Income (TTM)
-$137M
▲ +9.6% YoY
Op. Margin
-149.39%
▲ +35.1pp YoY
ROIC
-78.49%
▲ +4.5pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$115M
▼ -13.4% YoY
Op. Cash Flow (TTM)
-$115M
▼ -14.0% YoY
Net Debt
-$110M
Net Cash Position
Cash & Equiv.
$231M
3Y CAGR: -27.1%
Continue Research